Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 21, 2011

Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of CYP2C9*2/*3 polymorphisms

Mario Toriello, Pasquale Meccariello, Cristina Mazzaccara, Rosanna Di Fiore, Carmela Esposito and Lucia Sacchetti

Abstract

Background: Pharmacogenetic testing for drug-metabolizing enzymes is not yet widely used in clinical practice.

Methods: In an attempt to facilitate the application of this procedure, we have compared two real-time PCR-based methods, the TaqMan® and the LightCycler™ for the pharmacogenetic evaluation of CYP2C9*2/*3 polymorphisms.

Results and Conclusion: Both procedures are suitable for pharmacogenetic studies. The TaqMan procedure was less expensive in terms of cost per sample, but the TaqMan apparatus is more expensive than the LightCycler apparatus.


Corresponding author: Lucia Sacchetti, Dipartimento di Biochimica e Biotecnologie Mediche, Università di Napoli Federico II, via S. Pansini 5, 80131 Naples, Italy Phone: +39-081-7463532, Fax: +39-081-7462404,

References

1. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics 2005; 15:365–9.10.1097/01213011-200505000-00013Search in Google Scholar

2. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interaction and pharmacogenetics. Annu Rev Pharmacol Toxicol 2005; 45:477–94.10.1146/annurev.pharmtox.45.120403.095821Search in Google Scholar

3. Kirchheiner J, Brockmőller J. Clinical consequences of cytochrome P4502C9 polymorphisms. Clin Pharmacol Ther 2005; 77:1–16.10.1016/j.clpt.2004.08.009Search in Google Scholar

4. You JHS, Chan FWH, Wong RSM, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy – a decision analysis. Thromb Haemost 2004; 92:590–7.10.1160/TH04-03-0161Search in Google Scholar

5. Takahashi H, Wilkinson GR, Padrini R, Echizen H. CYP2C9 and oral anticoagulation therapy with acenocumarol and warfarin: similarities yet differences. Clin Pharmacol Ther 2004; 75:376–80.10.1016/j.clpt.2004.01.007Search in Google Scholar

6. Jannetto PJ, Laleli-Sahin E, Wong SH. Pharmacogenomics genotyping methodologies. Clin Chem Lab Med 2004; 42:1256–64.10.1515/CCLM.2004.246Search in Google Scholar

7. Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, Di Xu C, et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 2003; 17:373–6.10.1046/j.1472-8206.2003.00148.xSearch in Google Scholar

8. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′-nuclease assay. Genet Anal 1999; 14:143–9.10.1016/S1050-3862(98)00019-9Search in Google Scholar

9. Burian M, Grösch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. J Clin Pharmacol 2002; 54:518–21.10.1046/j.1365-2125.2002.01693.xSearch in Google Scholar PubMed PubMed Central

10. Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem 1997; 245:154–60.10.1006/abio.1996.9916Search in Google Scholar PubMed

11. Spreafico M, Peyvandi F, Pizzotti D, Moia M, Mannucci M. Warfarin and acenocumarol dose requirements according to CYP2C9 genotype in North-Italian patients [letter]. J Thromb Haemost 2004; 1:2252–3.10.1046/j.1538-7836.2003.00442.xSearch in Google Scholar PubMed

12. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004; 50:195–200.10.1016/j.phrs.2004.01.004Search in Google Scholar PubMed

Received: 2005-7-27
Accepted: 2005-12-1
Published Online: 2011-9-21
Published in Print: 2006-3-1

©2006 by Walter de Gruyter Berlin New York